Neoadjuvant Approaches for Renal Cell Carcinoma | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways Dr Naomi Haas discusses the feasibility of neoadjuvant therapy in RCC, highlighting the PROSPER trial's results and its role in treating unresectable disease.

What did the PROSPER trial teach us about neoadjuvant therapy in #RenalCellCarcinoma—and what questions still remain? Our GU #Cancer Committee Chair Dr. Naomi Haas shares lessons learned and practical considerations: bit.ly/4vsG8Zd #KidneyCancer #RCC

Attending #AACR26 next week and interested in #RealWorldEvidence and #ClinicalTrial design? Don't miss Session MW04: Clinical Trial Design Workshop chaired by @eaonc.bsky.social Group Co Chair Dr. Peter O'Dwyer
🗓 Apr 17 | 3–4:30 PM | Room 31 #RWE #CancerResearch

Proposed #NIH funding cuts and grant changes in the FY 2027 budget request could significantly slow progress in #CancerResearch—and ultimately impact patients. Read more via @ascocancer.bsky.social: bit.ly/4e6TX9p

📊 How can #RealWorldData strengthen cancer #ClinicalTrial design? At #AACR26, join Session MW04: Clinical Trial Design Workshop – #RealWorldEvidence in Clinical Trial Design, chaired by @eaonc.bsky.social Group Co Chair Dr. Peter O'Dwyer🗓 Apr 17 | 3–4:30 PM | Room 31 #RWE #CancerResearch

Bloodlines Series: What Is Smoldering Myeloma? Learn what is smoldering myeloma and about the first treatment approved by the FDA to prevent its progression to active multiple myeloma.

Early treatment for high risk #SmolderingMyeloma is no longer hypothetical—it’s FDA approved. Now #ClinicalTrials like EAA173 (DETER SMM) are critical to determine who benefits most and how much treatment is enough. Learn more about #SMM: bit.ly/4bVbJdk #MultipleMyeloma

EA8231 Research Study for Patients With Advanced Urothelial Cancer Study chair Dr. Monika Joshi and co-chair Dr. Petros Grivas discuss this trial that aims to improve outcomes for patients with anti-PD(L)1-resistant advanced urothelial cancer.

New video: Dr. Monika Joshi & @pgrivasmdphd.bsky.social discuss the EA8231 #ClinicalTrial, which aims to evaluate and answer the critical question of #immunotherapy (anti-PD1/L1) rechallenge in #UrothelialCancer therapy. Watch here: bit.ly/47UxFnr #BladderCancer

At #SSO2026 in early March, Dr. Maheswari Senthil presented results from the phase 2 STOPGAP trial for patients with #GastricCancer. This study laid the groundwork for ECOG-ACRIN Cancer Research Group's STOPGAP II, currently enrolling patients! More: bit.ly/47Bhbk1

Urothelial cancer is the most common type of #bladdercancer. The EA8192 study is evaluating durvalumab and chemotherapy for patients with high grade upper tract urothelial cancer prior to nephroureterectomy. bit.ly/ea8192-trial

NIH research grant funding rates plummeted in 2025 Agency acknowledges young investigators are losing out as result of multiyear funding policy imposed by White House

New data show #NIH research grant success rates plummeted in 2025—falling to around ~19–20% overall & hitting early-career scientists especially hard. The ripple effects could shape the biomedical workforce for years. More: bit.ly/46PsJjq #ResearchFunding #SciencePolicy

Primary Analysis and Results of Bendamustine, Rituximab, and Venetoclax (BR-VEN) for Initial Treatment of Mantle Cell Lymphoma in Subjects over 60 Years of Age (PrE0405) BackgroundMantle cell lymphoma (MCL) is an incurable form of aggressive non-Hodgkin lymphoma. Treatment choice at diagnosis is based on tolerability o…

#FindingsFriday: ICYMI, new data from @precogonc.bsky.social PrE0405, presented at #ASH25, showed that treatment with BR-VEN led to high response rates & promising CR rates for older patients w/ mantle cell #lymphoma. More: bit.ly/4aReE69 #MCL

Redefining Frontline Therapy in Undifferentiated Pleomorphic Sarcoma | CancerNetwork Seth M. Pollack, MD, discussed how the ECOG-ACRIN EA7222 trial could establish doxorubicin/pembrolizumab as the new frontline standard for undifferentiated pleomorphic sarcoma.

Debate continues: should #immunotherapy move earlier in undifferentiated pleomorphic #sarcoma ( #UPS ) care? Insights from Dr. Seth Pollack and the ECOG-ACRIN EA7222 trial shed light on evolving treatment paradigms. Watch the video: bit.ly/3OVL3ky

‼️ New #ComboMATCH updates are enhancing patient care: ctDNA-based screening and progression biopsy results returned to treating physicians to inform future treatment decisions, advancing #PrecisionOncology for patients with specific DNA alterations. More ➡️ bit.ly/46Vdbug

Opinion | The case for more personalized breast cancer screening Why cancer screening should become more like heart disease prevention.

In the @washingtonpost.com, Dr. Leana Wen argues for more personalized #BreastCancer screening—moving beyond 1-size-fits-all mammograms. That’s exactly what our #TMIST trial is evaluating: how 3D tomo compares to standard mammography & who benefits most. More: bit.ly/4rYQHRf

Trial Activation: EA6232, led by Dr. John Kirkwood of UPMC, is a phase II double-blind trial of sulforaphane for therapeutic prevention of #Melanoma in patients with multiple atypical nevi and a prior history of melanoma. Learn more: bit.ly/EA6232

We’re headed back to Baltimore! The ECOG-ACRIN Spring 2026 Group Meeting will be held May 5–7, 2026 (Tues–Thurs, note the shift from Wed–Fri). Join us in Baltimore for plenary sessions, networking, and collaboration. Stay tuned for registration details. #EAOnc

On #WorldCancerDay, we thank the patients, advocates, clinicians, and research teams who make ECOG-ACRIN trials possible. Your participation drives discovery and delivers hope. #CancerCare #UnitedByUnique

Fellows: Apply by 2/19 for the 2026 Paul Carbone, MD Fellowship Award, a research grant for senior oncology or hematology fellows that aims to develop & promote excellence in #clinicaltrials. Learn more: bit.ly/ea-carbone #cancerresearch

EA1241, led by Dr. Joseph Sparano of The Mount Sinai Hospital, is a companion study for patients who previously took part in either the TAILORx (PACCT-1) or RxPONDER (S1007) breast cancer trials. Learn more: bit.ly/EA1241

The nomination period is now open for the 2026
@eaonc.bsky.social Young Investigator Award! 🩺

This honor recognizes the scientific achievements of early-career investigators. Learn more & nominate a colleague by 2/19: bit.ly/ea-yia #mentorship #CancerResearch #ClinicalTrials

More people are living 5 years after cancer diagnosis, new data shows The five-year relative survival for all cancers combined has reached a milestone, according to the American Cancer Society.

#Cancer #survivorship is up—but sustained research funding and equitable access to screening & treatment are key to continued progress. Learn more via ABC News: bit.ly/3NvFTv0 #CancerPolicy #CancerResearch

EA is hosting a webinar on EA1241, a companion study for pts previously enrolled in TAILORx or RxPONDER. Investigators & #ClinicalResearch professionals are invited to register below.

📅Feb 4 | 4 PM ET
🎙 Joseph Sparano, MD, Kevin Kalinsky, MD, MS, & Rima Patel, MD
🔗https://bit.ly/EA1241webinar

Federal Funding for Cancer Research As Congress negotiates Fiscal Year 2025 appropriations bills, urge them to make cancer research a top priority.

DYK funding for NIH and NCI ends on 1/30? Act now & ask Congress to support sustainable, long-term funding for biomedical & #CancerResearch for FY26: bit.ly/3LpZJau

Otis Brawley looks back on a year of great science and greater challenges - The Cancer Letter In a year that brought us new KRAS-inhibiting drugs, deepened our understanding of HER2 in breast cancer, and highlighted new potential for mRNA vaccines, the cancer field was also rocked by uncertain...

“This is a great time to be in hashtag#oncology” — and also a time to rebuild how we support hashtag#science, access, & policy, says Dr. Otis Brawley, chair of our Social Determinants of Health Working Group. Catch his reflections in The Cancer Letter: bit.ly/4pgVzPX #SciencePolicy #SDOH

December 2025 Research Round-Up Read about the latest clinical trial findings in breast cancer, hematology research, precision medicine, and PrECOG studies.

#FindingsFriday: Don’t miss the newest round-up of recently presented findings from ECOG-ACRIN Cancer Research Group & PrECOG Cancer Research Group #ClinicalTrials. See key #CancerResearch results and why they matter: bit.ly/3YI9raZ #BreastCancer #Leukemia #Lymphoma

What I’ve learned by mapping the impacts of NIH cuts The co-founder of SCIMaP looks at the year of NIH cuts — and what they say about the future of American research.

What happens when #ResearchFunding slows? A new analysis looks at stalled studies, delayed discoveries, and the challenges researchers face navigating uncertainty. Read more: bit.ly/44FKmRI #NIH

AI Model Improves Prediction of Early and Late Breast Cancer Recurrence Joseph A. Sparano details multimodal approach outperforming the 21-gene recurrence score

ICYMI: Watch Joseph A. Sparano, MD, FACP discuss initial findings from a public-private partnership between ECOG-ACRIN & Caris Life Sciences to improve recurrence risk assessment in early-stage #BreastCancer using #ArtificialIntelligence. Video via MedPage Today: bit.ly/48R3uNN #bcsm #AI #SABCS25

Anthony Letai pledges to ensure stability for extramural and intramural cancer science - The Cancer Letter Stepping into the NCI director’s job at the end of a nerve-racking year, Anthony Letai wants you to know that the federal government is not going out of the business of cancer research. To access this...

Support for collaborative, federally funded #CancerResearch remains essential. The NCI Director Dr. Tony Letai shares his perspective on sustaining this work in a conversation with The Cancer Letter. Read the interview: bit.ly/3Mzqnhd

ECOG-ACRIN, Caris present breast cancer recurrence and risk stratification AI tools - The Cancer Letter Researchers have presented the initial findings from a major multi-year collaboration between the ECOG-ACRIN Cancer Research Group and Caris Life Sciences focused on transforming recurrence risk assessment in early-stage breast cancer through artificial intelligence. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or […]

ECOG-ACRIN, Caris present breast cancer recurrence and risk stratification AI tools (@eaonc.bsky.social)
https://cancerletter.com/clinical-roundup/20251212_6a/

Guide to SABCS 2025: ECOG-ACRIN research at the world’s largest breast cancer conference Learn about the multiple breast cancer research discoveries made by the group that will be included at the 2025 San Antonio Breast Cancer Symposium

Attending #SABCS25 this week? View this helpful guide to
@eaonc.bsky.social research at the meeting, including data from an exciting TAILORx correlative science initiative. More: bit.ly/4iTDohN #BreastCancer #bcsm

Black Patients With AML Face Lower Survival Outcomes | CURE Race has been identified as an independent prognostic factor in patients with AML receiving intensive chemotherapy.

New analysis of 10 ECOG-ACRIN Cancer Research Group trials shows that for Black #AML patients, survival advantage typically linked to certain mutations (like NPM1) doesn’t hold—highlighting a need to rethink how genetic risk factors are applied across racial groups. More: bit.ly/4pqT92h #ASH25